Recommendations for the reporting harms in manuscripts on clinical trials assessing osteoarthritis drugs: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).
[en] Background : There is strong evidence of under-reporting of harms in manuscripts on randomized controlled trials (RCTs) compared with the volume of raw data retrieved from these trials. Many guidelines have been developed to tackle this, but they have failed to address some important issues that would allow for standardization and transparency. As a consequence, harms reporting in manuscripts remains suboptimal.
Objective: The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) aimed to deliver accurate recommendations for better reporting of harms in clinical trials manuscripts on anti-osteoarthritis (OA) drugs. These could help to better inform clinicians on harms recorded in RCTs and further help researchers conducting meta-analyses.
Methods: Using the outcomes of several systematic reviews on the safety of anti-OA drugs, we summarized the ways in which harms have been reported in OA RCT manuscripts to date. Next, we drafted some recommendations and initiated a modified Delphi process that involved a panel of clinicians and clinical researchers to build an expert consensus on recommendations from the ESCEO for the reporting of harms in future manuscripts on RCTs assessing anti-OA drugs.
Results: These recommendations emphasize that all treatment-emergent adverse events (AEs) should always be taken into account for harms reporting, with no frequency threshold, and describe how specific AEs should be reported; they also provide a list of the most relevant organ systems to be considered according to each class of drug for reporting of harms within the results
section of a manuscript. Irrespective of the drug, the ESCEO recommends that total, severe and serious AEs and withdrawals due to AEs should always be reported; guidance on the reporting of specific events pertaining to each category is provided. The ESCEO also recommends the reporting of information on drug effect on biological parameters, with specific guidance. Conclusions These recommendations may contribute to improve transparency in the field of safety of anti-OA edications. Pharmaceutical companies developing drugs for OA, and researchers conducting clinical trials, are encouraged to comply with them when reporting harms-related results in manuscripts on RCTs. The ESCEO also encourages journals to refer to the ESCEO recommendations in their instructions to authors for the publication of manuscripts on trials of anti-OA medications.
Disciplines :
Public health, health care sciences & services General & internal medicine
Author, co-author :
Honvo, Germain ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie clinique
Bannuru, Raveendhara R.
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Rannou, F.
Herrero-Beaumont, G
Uebelhart, D.
Cooper, C.
Arden, N.
Conaghan, P.G.
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Thomas, T.
McAlindon, T.
Language :
English
Title :
Recommendations for the reporting harms in manuscripts on clinical trials assessing osteoarthritis drugs: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).
Ioannidis JPA, Lau J. Completeness of safety reporting in randomized trials. JAMA. 2001;285(4):437–43. 10.1001/jama.285.4.437.
Golder S, Loke YK, Wright K, Norman G. Reporting of adverse events in published and unpublished studies of health care interventions: a systematic review. PLoS Med. 2016;13(9):1–22. 10.1371/journal.pmed.1002127.
Rodgers MA, Brown JVE, Heirs MK, Higgins JPT, Mannion RJ, Simmonds MC, et al. Reporting of industry funded study outcome data: comparison of confidential and published data on the safety and effectiveness of rhBMP-2 for spinal fusion. BMJ (Online). 2013;347(7915):1–14. 10.1136/bmj.f3981.
Schroll JB, Penninga EI, Gøtzsche PC. Assessment of adverse events in protocols, clinical study reports, and published papers of trials of orlistat: a document analysis. PLoS Med. 2016;13(8):1–14. 10.1371/journal.pmed.1002101.
Hodkinson A, Gamble C, Smith CT. Reporting of harms outcomes: a comparison of journal publications with unpublished clinical study reports of orlistat trials. Trials. 2016;17(1):1–11. 10.1186/s13063-016-1327-z.
Smith SM, Chang RD, Pereira A, Shah N, Gilron I, Katz NP, et al. Adherence to CONSORT harms-reporting recommendations in publications of recent analgesic clinical trials: an ACTTION systematic review. Pain. 2012;153(12):2415–21. 10.1016/j.pain.2012.08.009.
Péron J, Maillet D, Gan HK, Chen EX, You B. Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review. J Clin Oncol. 2013;31(31):3957–63. 10.1200/JCO.2013.49.3981.
Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med. 2009;169(19):1756–61. 10.1001/archinternmed.2009.306.
Ioannidis JPA, Evans SJW, Gøtzsche PC, O’Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141(10):781–8. 10.7326/0003-4819-141-10-200411160-00009.
Haidich AB, Birtsou C, Dardavessis T, Tirodimos I, Arvanitidou M. The quality of safety reporting in trials is still suboptimal: survey of major general medical journals. J Clin Epidemiol. 2011;64(2):124–35. 10.1016/j.jclinepi.2010.03.005.
Hodkinson A, Kirkham JJ, Tudur-Smith C, Gamble C. Reporting of harms data in RCTs: a systematic review of empirical assessments against the CONSORT harms extension. BMJ Open. 2013;3(9):1–8. 10.1136/bmjopen-2013-003436.
Sivendran S, Latif A, McBride RB, Stensland KD, Wisnivesky J, Haines L, et al. Adverse event reporting in cancer clinical trial publications. J Clin Oncol. 2014;32(2):83–9. 10.1200/JCO.2013.52.2219.
Lineberry N, Berlin JA, Mansi B, Glasser S, Berkwits M, Klem C, et al. Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective. BMJ (Online). 2016;355:i5078. 10.1136/bmj.i5078.
Cornelius VR, Sauzet O, Williams JE, Ayis S, Farquhar-Smith P, Ross JR, et al. Adverse event reporting in randomised controlled trials of neuropathic pain: considerations for future practice. Pain. 2013;154(2):213–20. 10.1016/j.pain.2012.08.012.
Smith SM, Wang AT, Katz NP, McDermott MP, Burke LB, Coplan P, et al. Adverse event assessment, analysis, and reporting in recent published analgesic clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154(7):997–1008. 10.1016/j.pain.2013.03.003.
Juhl C, Lund H, Roos EM, Zhang W, Christensen R. A hierarchy of patient-reported outcomes for meta-analysis of knee osteoarthritis trials: empirical evidence from a survey of high impact journals. Arthritis. 2012;2012:1–17. 10.1155/2012/136245.
Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol. 1997;24(4):799–802. 10.1080/00913847.2015.1025029.
Hrnack SA, Barber FA. Managing the pain of knee osteoarthritis. Physician Sportsmed. 2014;42(3):63–70. 10.3810/psm.2014.09.2077.
Yang W, Liu W, Miao C, Sun H, Li L, Li C. Oral glucosamine hydrochloride combined with hyaluronate sodium intra-articular injection for temporomandibular joint osteoarthritis: a double-blind randomized controlled trial. J Oral Maxillofac Surg. 2018;76(10):2066–73. 10.1016/j.joms.2018.04.031.
Wang SZ, Wu DY, Chang Q, Guo YD, Wang C, Fan WM. Intra-articular, single-shot co-injection of hyaluronic acid and corticosteroids in knee osteoarthritis: a randomized controlled trial. Exp Ther Med. 2018;16(3):1928–34. 10.3892/etm.2018.6371.
Petterson SC, Plancher KD. Single intra-articular injection of lightly cross-linked hyaluronic acid reduces knee pain in symptomatic knee osteoarthritis: a multicenter, double-blind, randomized, placebo-controlled trial. Knee Surg Sports Traumatol Arthrosc. 2018. 10.1007/s00167-018-5114-0.
Brander V, Skrepnik N, Petrella RJ, Jiang GL, Accomando B, Vardanyan A. Evaluating the use of intra-articular injections as a treatment for painful hip osteoarthritis: a randomized, double-blind, multicenter, parallel-group study comparing a single 6-mL injection of hylan G-F 20 with saline. Osteoarthr Cartil. 2018. 10.1016/j.joca.2018.08.018.
Williams MR, McKeown A, Pressman Z, Hunsinger M, Lee K, Coplan P, et al. Adverse event reporting in clinical trials of intravenous and invasive pain treatments: an ACTTION systematic review. J Pain. 2016;17(11):1137–49. 10.1016/j.jpain.2016.07.006.
Hoffer D, Smith SM, Parlow J, Allard R, Gilron I. Adverse event assessment and reporting in trials of newer treatments for post-operative pain. Acta Anaesthesiol Scand. 2016;60(7):842–51. 10.1111/aas.12721.
Hadi MA, McHugh GA, Conaghan PG. Quality of reporting of harms in randomised controlled trials of pharmacological interventions for rheumatoid arthritis: a systematic review. Evid Based Med. 2017. 10.1136/ebmed-2017-110715.
ICH. Clinical safety data management: definitions and standards for expedited reporting E2A. 27 October 1994.
Parliament EU. Directive 2001/20/EC of the European Parliament and of the council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off J Eur Communities. 2001;L121/34.
Commission EU. Communication from the Commission: Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use (CT-3) 11.6.2011. Report no.: 2011/c 172/01.
Honvo G, Leclercq V, Geerinck A, Thomas T, Veronese N, Charles A, et al. Safety of topical non-steroidal anti-inflammatory drugs in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36(Suppl. 1). 10.1007/s40266-019-00661-0.
Honvo G, Reginster J-Y, Rabenda V, Geerinck A, Mkinsi O, Charles A, et al. Safety of symptomatic slow-acting drugs for osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36(Suppl. 1). 10.1007/s40266-019-00662-z.
Honvo G, Reginster JY, Rannou F, Rygaert X, Geerinck A, Rabenda V, et al. Safety of intra-articular hyaluronic acid injections in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36(Suppl. 1). 10.1007/s40266-019-00657-w.
Hsu C-C, Sandford BA. The Delphi technique: making sense of consensus. Pract Assess Res Eval. 2007;12:1–8.
Dalkey N, Helmer O. An experimental application of the delphi method to the use of experts. Manag Sci. 1963;9(3):458–67.
Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess (Winch Engl). 1998;2(3):1–88. 10.3310/hta2030.
Altman RD, Dreiser RL, Fisher CL, Chase WF, Dreher DS, Zacher J. diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009;36(9):1991–9. 10.3899/jrheum.081316.
Barthel HR, Haselwood D, Longley S, Gold MS, Altman RD. Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis. Semin Arthritis Rheum. 2009;39(3):203–12. 10.1016/j.semarthrit.2009.09.002.
Kneer W, Rother M, Mazgareanu S, Seidel EJ, European Idea-Study Group. A 12-week randomized study of topical therapy with three dosages of ketoprofen in Transfersome gel (IDEA-033) compared with the ketoprofen-free vehicle (TDT 064), in patients with osteoarthritis of the knee. J Pain Res. 2013;6(101540514):743–53. 10.2147/JPR.S51054.
ICH. ICH harmonised tripartite guideline Statistical principles for clinical trials. Stat Med. 1999;18:1903–4. 10.1002/(sici)1097-0258(19990815)18:15%3c1903:aid-sim188%3e3.0.co;2-f.
Altman RD, Akermark C, Beaulieu AD, Schnitzer T, Durolane International Study G. Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee. Osteoarthr Cartil. 2004;12(8):642–9.
Strand V, Baraf HS, Lavin PT, Lim S, Hosokawa H. A multicenter, randomized controlled trial comparing a single intra-articular injection of Gel-200, a new cross-linked formulation of hyaluronic acid, to phosphate buffered saline for treatment of osteoarthritis of the knee. Osteoarthr Cartil. 2012;20(5):350–6. 10.1016/j.joca.2012.01.013.
Conaghan PG, Dickson J, Bolten W, Cevc G, Rother M. A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis. Rheumatology (Oxford). 2013;52(7):1303–12. 10.1093/rheumatology/ket133.
Bookman AA, Williams KS, Shainhouse JZ. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ. 2004;171(4):333–8. 10.1503/cmaj.1031793.
Roth SH, Shainhouse JZ. Efficacy and safety of a topical diclofenac solution (pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Arch Intern Med. 2004;164(18):2017–23.
Baraf HS, Gold MS, Clark MB, Altman RD. Safety and efficacy of topical diclofenac sodium 1% gel in knee osteoarthritis: a randomized controlled trial. Phys Sportsmed. 2010;38(2):19.
Michel BA, Stucki G, Frey D, De Vathaire F, Vignon E, Bruehlmann P, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum. 2005;52(3):779–86. 10.1002/art.20867.
Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357(9252):251–6. 10.1016/S0140-6736(00)03610-2.
Pelletier JP, Yaron M, Haraoui B, Cohen P, Nahir MA, Choquette D, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000;43(10):2339–48.
Frestedt JL, Walsh M, Kuskowski MA, Zenk JL. A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized controlled pilot trial. Nutr J. 2008;7(101152213):9.
Niethard F, Gold MS, Solomon GS, Liu JM, Unkauf M, Albrecht HH, et al. Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee. J Rheumatol. 2005;32(12):2384.
Bruhlmann P, Michel BA. Topical diclofenac patch in patients with knee osteoarthritis: a randomized, double-blind, controlled clinical trial. Clin Exp Rheumatol. 2003;21(2):193–8.
Jorgensen A, Stengaard-Pedersen K, Simonsen O, Pfeiffer-Jensen M, Eriksen C, Bliddal H, et al. Intra-articular hyaluronan is without clinical effect in knee osteoarthritis: a multicentre, randomised, placebo-controlled, double-blind study of 337 patients followed for 1 year. Ann Rheum Dis. 2010;69(6):1097–102.
Huang T-L, Chang C-C, Lee C-H, Chen S-C, Lai C-H, Tsai C-L. Intra-articular injections of sodium hyaluronate (Hyalgan) in osteoarthritis of the knee. A randomized, controlled, double-blind, multicenter trial in the Asian population. BMC Musculoskelet Disord. 2011;12(100968565):221.
van der Weegen W, Wullems JA, Bos E, Noten H, van Drumpt RA. No difference between intra-articular injection of hyaluronic acid and placebo for mild to moderate knee osteoarthritis: a randomized, controlled, double-blind trial. J Arthroplast. 2015;30(5):754–7. 10.1016/j.arth.2014.12.012.
Karlsson J, Sjogren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology (Oxford, England). 2002;41(11):1240–8.
Allegrini A, Nuzzo L, Pavone D, Tavella-Scaringi A, Giangreco D, Bucci M, et al. Efficacy and safety of piroxicam patch versus piroxicam cream in patients with lumbar osteoarthritis. A randomized, placebo-controlled study. Arzneimittelforschung. 2009;59(8):403–9.
Rother M, Conaghan PG. A randomized, double-blind, phase III trial in moderate osteoarthritis knee pain comparing topical ketoprofen gel with ketoprofen-free gel. J Rheumatol. 2013;40(10):1742–8. 10.3899/jrheum.130192.
Arden NK, Akermark C, Andersson M, Todman MG, Altman RD. A randomized saline-controlled trial of NASHA hyaluronic acid for knee osteoarthritis. Curr Med Res Opin. 2014;30(2):279–86.
Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, Blanco FJ, Benito P, Martin-Mola E, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum. 2007;56(2):555–67. 10.1002/art.22371.
Rother M, Lavins BJ, Kneer W, Lehnhardt K, Seidel EJ, Mazgareanu S. Efficacy and safety of epicutaneous ketoprofen in transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial. Ann Rheum Dis. 2007;66(9):1178–83. 10.1136/ard.2006.065128.
Baer PA, Thomas LM, Shainhouse Z. Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886]. BMC Musculoskelet Disord. 2005;6:44. 10.1186/1471-2474-6-44.
Gabay C, Medinger-Sadowski C, Gascon D, Kolo F, Finckh A. Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center. Arthritis Rheum. 2011;63(11):3383–91.
Reginster JY, Dudler J, Blicharski T, Pavelka K. Pharmaceutical-grade chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis. 2017;76(9):1537–43. 10.1136/annrheumdis-2016-210860.
Roman-Blas JA, Castaneda S, Sanchez-Pernaute O, Largo R, Herrero-Beaumont G, Group CGCTS. Combined treatment with chondroitin sulfate and glucosamine sulfate shows no superiority over placebo for reduction of joint pain and functional impairment in patients with knee osteoarthritis: a six-month multicenter, randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol. 2017;69(1):77–85. 10.1002/art.39819.
Esfandiari H, Pakravan M, Zakeri Z, Ziaie S, Pakravan P, Ownagh V. Effect of glucosamine on intraocular pressure: a randomized clinical trial. Eye (London, England). 2017;31(3):389–94.
Bailey C, Peddie D, Wickham ME, Badke K, Small SS, Doyle-Waters MM, et al. Adverse drug event reporting systems: a systematic review. Br J Clin Pharmacol. 2016;82(1):17–29. 10.1111/bcp.12944.
Karmarkar A. Reporting adverse drug reactions: a view on ADR dictionaries. Pharma Utility. 2012;6(6):9–12.
Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109–17. 10.2165/00002018-199920020-00002.
Fescharek R, Kübler J, Elsasser U, Frank M, Güthlein P. Medical dictionary for regulatory activities (MedDRA). Int J Pharm Med. 2004;18(5):259–69. 10.2165/00124363-200418050-00001.
Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip. Arthritis Rheum. 2001;44(11):2539–47.
Morabia A. On the origin of Hill’s causal criteria. Epidemiology. 1991;2(5):367–9.
Morabia A. Hume, Mill, Hill, and the sui generis epidemiologic approach to causal inference. Am J Epidemiol. 2013;178(10):1526–32. 10.1093/aje/kwt223.
Weed DL. Interpreting epidemiological evidence: how meta-analysis and causal inference methods are related. Int J Epidemiol. 2000;29(3):387–90.
Perez C, Olivier P, Lortal B, Duranton S, Montastruc JL, Colin AL, et al. Detection of drug safety signals from clinical trials data: role of SUSARs. Pharmacol Res. 2018;131:218–23. 10.1016/j.phrs.2018.02.010.
Tsang R, Colley L, Lynd LD. Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials. J Clin Epidemiol. 2009;62(6):609–16. 10.1016/j.jclinepi.2008.08.005.
Papanikolaou PN, Christidi GD, Ioannidis JPA. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ. 2006;174(5):635–41. 10.1503/cmaj.050873.
Singh S, Loke YK. Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials. 2012;13:1–8. 10.1186/1745-6215-13-138.
Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ. 1995;311:485.
Slutsky D. Statistical errors in clinical studies. J Wrist Surg. 2013;02(04):285–7. 10.1055/s-0033-1359421.
Alderson P. Absence of evidence is not evidence of absence. BMJ. 2004;328(7438):476–7. 10.1136/bmj.328.7438.476.
Sedgwick P. What is sampling error? BMJ (Online). 2012;344(7863):1–2. 10.1136/bmj.e4285.
Altman DG, Bland JM. Uncertainty beyond sampling error. BMJ (Online). 2014;349(November):1–2. 10.1136/bmj.g7065.
Sedgwick P. Uncertainty in sample estimates: sampling error. BMJ. 2015;350:h1914. 10.1136/bmj.h1914.
Buyse M, Squifflet P, Coart E, Quinaux E, Punt CJA, Saad ED. The impact of data errors on the outcome of randomized clinical trials. Clin Trials. 2017;14(5):499–506. 10.1177/1740774517716158.
Gluud LL. Bias in clinical intervention research. AJE. 2006;163(6):493–501. 10.1093/aje/kwj069.
Keirse MJNC, Hanssens M. Control of error in randomized clinical trials. Eur J Obstet Gynecol Reprod Biol. 2000;92(1):67–74. 10.1016/S0301-2115(00)00455-3.
Sterne JAC, Smith GD. Sifting the evidence—what’s wrong with significance tests? Phys Ther. 2001;81(8):1464–9. 10.1093/ptj/81.8.1464.
ICH. Introductory guide MedDRA version 21.0 March 2018; Report no.: 000148.
Mansi BA, Clark J, David FS, Gesell TM, Glasser S, Gonzalez J, et al. Ten recommendations for closing the credibility gap in reporting industry-sponsored clinical research: a joint journal and pharmaceutical industry perspective. Mayo Clin Proc. 2012;87(5):424–9. 10.1016/j.mayocp.2012.02.009.
Favier R, Crepin S. The reporting of harms in publications on randomized controlled trials funded by the “Programme Hospitalier de Recherche Clinique,” a French academic funding scheme. Clin Trials. 2018;15(3):257–67. 10.1177/1740774518760565.
Kroon FPB, Carmona L, Schoones JW, Kloppenburg M. Efficacy and safety of non-pharmacological, pharmacological and surgical treatment for hand osteoarthritis: a systematic literature review informing the 2018 update of the EULAR recommendations for the management of hand osteoarthritis. RMD Open. 2018;4(2):e000734. 10.1136/rmdopen-2018-000734.
Golder S, Loke YK. Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies? Br J Clin Pharmacol. 2008;66(6):767–73. 10.1111/j.1365-2125.2008.03272.x.
Goldacre B, Lane S, Mahtani KR, Heneghan C, Onakpoya I, Bushfield I, et al. Pharmaceutical companies’ policies on access to trial data, results, and methods: audit study. BMJ (Online). 2017;358(July):1–12. 10.1136/bmj.j3334.
DeVito NJ, French L, Goldacre B. Noncommercial funders’ policies on trial registration, access to summary results, and individual patient data availability. JAMA. 2018;319(16):1721–3.
Mayo-Wilson E, Heyward J, Keyes A, Reynolds J, White S, Atri N, et al. Clinical trial registration and reporting: a survey of academic organizations in the United States. BMC Med. 2018;16(1):1–13. 10.1186/s12916-018-1042-6.
